'Inferior efficacy' leads to premature end of PhIII for Bayer's next-gen blood thinner asundexian
Bayer is bringing a Phase III trial for its blood thinner asundexian to an early end after the drug showed “inferior efficacy” against the control arm, the company announced Sunday.
OCEANIC-AF is the first of three large Phase III studies Bayer has planned for asundexian, a top late-stage candidate that executives said they “continue to feel very strong about” as recently as the third-quarter earnings call. It was designed to compare asundexian with Eliquis, or apixaban, a longstanding anticoagulant, in 18,000 patients with atrial fibrillation (AF) at risk for stroke. It was originally set to conclude in the summer of 2025, per a clinicaltrials.gov listing.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.